MASHINIi

GH Research PLC.

GHRS.US | Research and experimental development on natural sciences and engineering

GH Research PLC is a biotechnology company focused on developing novel therapies for the treatment of mental health disorders. The company's primary focus is on developing and commercializing 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) therapies for treatment-resistant depression (TRD). They conduc...Show More

Ethical Profile

Mixed.

GH Research PLC is dedicated to mental health treatments, with lead product GH001 showing promising Phase 2b results for treatment-resistant depression (57.5% remission) and 100% remission in a Phase 2a postpartum depression trial. However, the FDA has placed a clinical hold on GH001, requesting further studies. The company maintains a whistleblower policy, yet publicly available data is limited regarding its practices on fair pay, ethical sourcing, environmental impact, or animal welfare, making a comprehensive ethical assessment challenging.

Value Scores

Better Health for All40
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business-40
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech-10
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

40

GH Research PLC is entirely focused on developing therapies for mental health disorders, specifically treatment-resistant depression (TRD), postpartum depression, and bipolar II disorder.

1
Clinical trials for its drug candidate GH001 have shown significant positive health impacts. In a Phase 2b trial for TRD, a -15.5 point placebo-adjusted MADRS reduction was observed by Day 8, with a 57.5% remission rate for the GH001 group versus 0% for placebo.
2
An individualized dosing regimen showed an 87.5% remission rate in TRD patients.
3
For postpartum depression, all 10 participants in a Phase 2a trial achieved remission by Day 8, and a bipolar II trial showed a 52% mean reduction in depressive symptoms by Day 8.
4
The company's core business is directly aligned with mental health treatment. As a biotechnology company focused on developing therapies, it has no revenue from products with negative health outcomes, and its product development criteria are entirely health-benefit oriented. GH001 has been well-tolerated in all trials, with no severe or serious adverse events reported across three Phase 1 trials involving 78 participants, and no serious adverse events in the double-blind phase of the Phase 2b trial or its open-label extension as of January 22, 2025.
5
The company's clinical trials are randomized, double-blind, and placebo-controlled, and conducted under the supervision of qualified healthcare professionals.
6

Fair Money & Economic Opportunity

0

No evidence available to assess GH Research PLC on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess GH Research PLC on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No relevant data regarding GHRS.US's fair trade and ethical sourcing practices could be extracted from the provided articles, as all article links resulted in 'page not found' or 'no data extracted' errors.

1

Honest & Fair Business

-40

GH Research has a formal whistleblower policy that aligns with Irish, EU, and US law.

1
It includes internal reporting channels via a Whistlelink platform and accepts anonymous reports, outlining procedures for handling reports and protections against retaliation.
2
The policy commits to acknowledging receipt of reports within 7 days and providing feedback within 3 months.
3
However, there is no explicit evidence of independent investigation processes for these reports.

Kind to Animals

0

The provided articles are primarily financial reports and regulatory updates for GH Research PLC's drug development. They contain no specific, concrete information or data points regarding the company's animal testing policies, volume of animals used, cruelty-free certifications, use of alternative testing methods, ethical sourcing of ingredients, humane certifications for operations, wildlife conservation efforts, R&D investment in animal-free technologies, or engagement in animal welfare policy.

1
Therefore, no KPIs related to the 'Kind to Animals' value can be scored based on the evidence provided.

No War, No Weapons

0

No evidence available to assess GH Research PLC on No War, No Weapons.

Planet-Friendly Business

0

No specific, quantitative data relevant to the 'Planet-Friendly Business' ethical value for GH Research PLC (GHRS.US) was found in the provided articles. Articles explicitly about GHRS.US (Articles 0, 3, 4, 5, 6) state that no such data is present

1
2
3
4
5
or only provide a general ESG risk score without specific metrics.
6
Other articles containing environmental metrics (Articles 1 and 2) pertain to different companies (FQM and Gresham House, respectively), not GHRS.US operations.
7
8

Respect for Cultures & Communities

0

No specific, concrete evidence was found in the provided articles to score any of the KPIs related to 'Respect for Cultures & Communities'. The articles detail internal whistleblowing policies and a Code of Ethics, which are primarily focused on employee conduct and internal reporting channels, not explicitly on community engagement, cultural preservation, or specific mechanisms for addressing community concerns or cultural incidents as defined by the rubric's KPIs.

1

Safe & Smart Tech

-10

The company has no documented data breaches. It uses Secure Sockets Layer (SSL) certificates to encrypt data.

1
There are no documented incidents of unauthorized data use. Users can withdraw consent for data processing, request copies, and request removal of their personally identifiable information by contacting the company, with identity verification performed.
2
The company states it keeps personal information only as long as required, but specifies retention periods of up to 3 years for job application information and 6 years for employee files after employment ends.
3
The company complies with the Data Protection Act 2018 (incorporating GDPR) and is subject to various U.S. and foreign privacy and data security laws and regulations.
4

Zero Waste & Sustainable Products

0

No specific, concrete data points were found in the provided articles for GH Research PLC regarding its waste diversion rate, product recyclability, packaging sustainability, recycled content percentage, single-use plastic reduction, take-back program coverage, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability score, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

1
The articles primarily discuss financial performance, regulatory timelines, or general industry trends, without providing specific details on the company's waste and sustainable product practices.
2

Own GH Research PLC?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.